however, kissemia is out. i know the market opportunity is big but how do you make sure it is arena pharmaceuticals? >> no single drug is sufficient for orlanal indication. >> talk to an analyst this morning. we talked about marketing a drug. we have got to partner. what is going to justify the huge investment? research and development? >> it is the same company that introduced the first alzheimer's drug that is still used today. they have ten drugs that have been successful with. being quite successful with as well. >> he has gotten out. >> you're trying to diversify the risk. and the way we have diversified risk is we're a neurorow science company and we partnered one of our late stage products. they have a phase three clinical trials. then our second compound that we have moving along, we're keeping all to ourself. it's in movement disorders. we're tarking it to children next year. >> a medical insider said that you have got an easier time than jack did. the fda has become better and faster and when you wer